Bronchiectasis Clinical Research Study for adults, currently being treated with established therapy

Research Study for Bronchiectasis Treatment

Recruiting
18 years - 85 years
All
Phase 2
300 participants needed
9 Locations

Study Overview

This study is looking for individuals ages 18 to 85 with bronchiectasis who require treatment in addition to their current therapies.   Bronchiectasis is a long-lasting lung disease characterized by the enlargement of the air passages inside the lungs due to weakening of the airway vessel wall, which leads to symptoms such as shortness of breath, coughing up sputum and sometimes blood, wheezing (high pitch sound while breathing), and frequent lung infections.  

 

Available standard treatments for bronchiectasis are not always effective. The investigational medication (itepekimab) is being investigated as a possible treatment for bronchiectasis. It binds to a specific substance in the body that is crucial for the function of certain cells in our immune system.  Itepekimab is an injectable treatment and is administered under the skin (subcutaneously) via a prefilled syringe.  Injections will be given every two weeks.  

 

If you are interested in learning more about this study, we encourage you to complete a brief questionnaire to help determine if you may qualify to participate and be referred to a site recruiting in your area for further evaluation.

Study Details

This study will have about 300 participants in approximately 20 countries.   

 

All participants will receive either the investigational medication or placebo (in addition to their usual medications).   The treatment is randomly chosen for each participant.  There is a 2 in 3 chance of receiving the investigational medication.  

 

This study is a blinded study. Blinded means that neither the people taking part, nor the study doctors know who is given the investigational medicine or the placebo.

 

The total study duration will be between 44-77 weeks, depending on when you start the study.  Treatment will last at least 24 weeks and no longer than 52 weeks.  There will be 12 site visits and up to 5 phone visits.  Study tests include:

·         Physical exam

·         Vital signs

·         Medical history

·         Bronchiectasis severity index

·         Electrocardiogram (ECG)

·         Chest CT (computed tomography scan)

·         Spirometry

·         Blood and urine testing

·         Assessments / questionnaires

 

There is no cost to participate.  All study-related exams, study-related medications and study-related medical care is provided.  There is no insurance required to take part in this study.  You may be compensated for time and travel. 

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchiectasis
  • Age: Between 18 Years - 85 Years
  • Gender: All

 

Updated on 21 Jun 2024. Study ID: NCT06280391

This study investigates bronchiectasis, a chronic lung condition where the airways in the lungs become enlarged due to weakened walls. This can lead to symptoms like shortness of breath, coughing up mucus and sometimes blood, wheezing, and frequent lung infections. The study aims to explore the effects of an investigational medication, which is given as an injection under the skin, to see if it can be a treatment option for bronchiectasis.

Participants in the study will receive injections every two weeks. Some will receive the investigational medication, while others will get a placebo, which looks like the investigational medication but has no active ingredients. The study is double-blind, meaning neither participants nor doctors will know who receives the investigational medication or the placebo. Tests during the study include physical exams, vital signs, medical history, bronchiectasis severity index, ECG, chest CT scans, spirometry, and blood and urine tests.

  • Who can participate: Adults aged 18 to 85 who have bronchiectasis may be eligible to participate. The study is open to all genders.
  • Study details: Participants will receive either the investigational medication or a placebo, in addition to their usual treatments. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study is double-blind, so neither participants nor doctors know who receives which treatment.
  • Study Visits: The study requires 12 visits.

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language